Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPR) saw a large growth in short interest in December. As of December 15th, there was short interest totaling 3,455,246 shares, a growth of 88.6% from the November 30th total of 1,831,825 shares. Approximately 12.9% of the company’s shares are short sold. Based on an average trading volume of 6,402,040 shares, the days-to-cover ratio is presently 0.5 days. Based on an average trading volume of 6,402,040 shares, the days-to-cover ratio is presently 0.5 days. Approximately 12.9% of the company’s shares are short sold.

Jasper Therapeutics Stock Down 3.8%

JSPR traded down $0.07 during trading hours on Friday, hitting $1.76. The stock had a trading volume of 442,419 shares, compared to its average volume of 3,957,529. The company’s fifty day simple moving average is $1.90 and its 200 day simple moving average is $2.85. Jasper Therapeutics has a 1 year low of $1.39 and a 1 year high of $22.99. The stock has a market cap of $49.24 million, a PE ratio of -0.30 and a beta of 3.06.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.12). As a group, equities analysts expect that Jasper Therapeutics will post -4.47 EPS for the current year.

Institutional Trading of Jasper Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Velan Capital Investment Management LP grew its holdings in shares of Jasper Therapeutics by 86.1% during the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after purchasing an additional 1,234,567 shares in the last quarter. Acorn Capital Advisors LLC bought a new stake in Jasper Therapeutics during the third quarter valued at approximately $3,291,000. Kingdon Capital Management L.L.C. lifted its position in Jasper Therapeutics by 93.5% during the third quarter. Kingdon Capital Management L.L.C. now owns 1,324,845 shares of the company’s stock valued at $3,153,000 after purchasing an additional 640,138 shares during the last quarter. Woodline Partners LP purchased a new position in Jasper Therapeutics in the 3rd quarter worth approximately $2,475,000. Finally, Vanguard Group Inc. increased its holdings in shares of Jasper Therapeutics by 65.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,032,842 shares of the company’s stock worth $2,458,000 after buying an additional 408,245 shares during the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. BTIG Research reduced their price target on shares of Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating for the company in a report on Monday, September 22nd. JMP Securities cut their price objective on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Monday, September 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Wednesday, October 8th. Finally, Evercore ISI decreased their target price on Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a research report on Monday, September 22nd. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Hold” and an average price target of $20.29.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.